213 related articles for article (PubMed ID: 22827500)
1. Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic.
Thomas TP; Huang B; Choi SK; Silpe JE; Kotlyar A; Desai AM; Zong H; Gam J; Joice M; Baker JR
Mol Pharm; 2012 Sep; 9(9):2669-2676. PubMed ID: 22827500
[TBL] [Abstract][Full Text] [Related]
2. Bifunctional PAMAM dendrimer conjugates of folic acid and methotrexate with defined ratio.
Zong H; Thomas TP; Lee KH; Desai AM; Li MH; Kotlyar A; Zhang Y; Leroueil PR; Gam JJ; Banaszak Holl MM; Baker JR
Biomacromolecules; 2012 Apr; 13(4):982-91. PubMed ID: 22360561
[TBL] [Abstract][Full Text] [Related]
3. Folate Receptor-Targeted Dendrimer-Methotrexate Conjugate for Inflammatory Arthritis.
Qi R; Majoros I; Misra AC; Koch AE; Campbell P; Marotte H; Bergin IL; Cao Z; Goonewardena S; Morry J; Zhang S; Beer M; Makidon P; Kotlyar A; Thomas TP; Baker JR
J Biomed Nanotechnol; 2015 Aug; 11(8):1431-41. PubMed ID: 26295143
[TBL] [Abstract][Full Text] [Related]
4. PSMA-targeted stably linked "dendrimer-glutamate urea-methotrexate" as a prostate cancer therapeutic.
Huang B; Otis J; Joice M; Kotlyar A; Thomas TP
Biomacromolecules; 2014 Mar; 15(3):915-23. PubMed ID: 24392665
[TBL] [Abstract][Full Text] [Related]
5. Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates.
Myc A; Douce TB; Ahuja N; Kotlyar A; Kukowska-Latallo J; Thomas TP; Baker JR
Anticancer Drugs; 2008 Feb; 19(2):143-9. PubMed ID: 18176110
[TBL] [Abstract][Full Text] [Related]
6. Targeting and inhibition of cell growth by an engineered dendritic nanodevice.
Thomas TP; Majoros IJ; Kotlyar A; Kukowska-Latallo JF; Bielinska A; Myc A; Baker JR
J Med Chem; 2005 Jun; 48(11):3729-35. PubMed ID: 15916424
[TBL] [Abstract][Full Text] [Related]
7. Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent.
Zhang Y; Thomas TP; Lee KH; Li M; Zong H; Desai AM; Kotlyar A; Huang B; Holl MM; Baker JR
Bioorg Med Chem; 2011 Apr; 19(8):2557-64. PubMed ID: 21459000
[TBL] [Abstract][Full Text] [Related]
8. Avidity modulation of folate-targeted multivalent dendrimers for evaluating biophysical models of cancer targeting nanoparticles.
Silpe JE; Sumit M; Thomas TP; Huang B; Kotlyar A; van Dongen MA; Banaszak Holl MM; Orr BG; Choi SK
ACS Chem Biol; 2013 Sep; 8(9):2063-71. PubMed ID: 23855478
[TBL] [Abstract][Full Text] [Related]
9. Sequence-Defined Oligoamide Drug Conjugates of Pretubulysin and Methotrexate for Folate Receptor Targeted Cancer Therapy.
Truebenbach I; Gorges J; Kuhn J; Kern S; Baratti E; Kazmaier U; Wagner E; Lächelt U
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28371444
[TBL] [Abstract][Full Text] [Related]
10. Targeted dendrimeric anticancer prodrug: a methotrexate-folic acid-poly(amidoamine) conjugate and a novel, rapid, "one pot" synthetic approach.
Zhang Y; Thomas TP; Desai A; Zong H; Leroueil PR; Majoros IJ; Baker JR
Bioconjug Chem; 2010 Mar; 21(3):489-95. PubMed ID: 20128612
[TBL] [Abstract][Full Text] [Related]
11. Design considerations for PAMAM dendrimer therapeutics.
Goonewardena SN; Kratz JD; Zong H; Desai AM; Tang S; Emery S; Baker JR; Huang B
Bioorg Med Chem Lett; 2013 May; 23(10):2872-5. PubMed ID: 23583511
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms and implications of dual-acting methotrexate in folate-targeted nanotherapeutic delivery.
Wong PT; Choi SK
Int J Mol Sci; 2015 Jan; 16(1):1772-90. PubMed ID: 25590303
[TBL] [Abstract][Full Text] [Related]
13. Photochemical release of methotrexate from folate receptor-targeting PAMAM dendrimer nanoconjugate.
Choi SK; Thomas TP; Li MH; Desai A; Kotlyar A; Baker JR
Photochem Photobiol Sci; 2012 Apr; 11(4):653-60. PubMed ID: 22234658
[TBL] [Abstract][Full Text] [Related]
14. Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic Acid-multiwalled carbon nanotube conjugate.
Das M; Datir SR; Singh RP; Jain S
Mol Pharm; 2013 Jul; 10(7):2543-57. PubMed ID: 23683251
[TBL] [Abstract][Full Text] [Related]
15. Integration of phospholipid-hyaluronic acid-methotrexate nanocarrier assembly and amphiphilic drug-drug conjugate for synergistic targeted delivery and combinational tumor therapy.
Li Y; Zhang H; Chen Y; Ma J; Lin J; Zhang Y; Fan Z; Su G; Xie L; Zhu X; Hou Z
Biomater Sci; 2018 Jun; 6(7):1818-1833. PubMed ID: 29785434
[TBL] [Abstract][Full Text] [Related]
16. Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis.
Thomas TP; Goonewardena SN; Majoros IJ; Kotlyar A; Cao Z; Leroueil PR; Baker JR
Arthritis Rheum; 2011 Sep; 63(9):2671-80. PubMed ID: 21618461
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells.
Barar J; Kafil V; Majd MH; Barzegari A; Khani S; Johari-Ahar M; Asgari D; Coukos G; Omidi Y
J Nanobiotechnology; 2015 Mar; 13():26. PubMed ID: 25880772
[TBL] [Abstract][Full Text] [Related]
18. Targeting the efficacy of a dendrimer-based nanotherapeutic in heterogeneous xenograft tumors in vivo.
Myc A; Kukowska-Latallo J; Cao P; Swanson B; Battista J; Dunham T; Baker JR
Anticancer Drugs; 2010 Feb; 21(2):186-92. PubMed ID: 20010426
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate-gelonin conjugate - an inhibitor of MCF-7 cells expressing the dihydrofolate receptor.
Badr M; Kopp C; Theison S; Meyer J; Trommer WE
Biol Chem; 2014 Dec; 395(12):1461-6. PubMed ID: 25205711
[TBL] [Abstract][Full Text] [Related]
20. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines.
Gurdag S; Khandare J; Stapels S; Matherly LH; Kannan RM
Bioconjug Chem; 2006; 17(2):275-83. PubMed ID: 16536456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
